Wuxi Biologics
Wuxi Biologics, officially known as WuXi AppTec Co., Ltd., is a leading global contract research, development, and manufacturing organisation (CDMO) headquartered in Wuxi, China. Founded in 2010, the company has rapidly expanded its operations across major regions, including the United States and Europe, establishing itself as a key player in the biopharmaceutical industry. Specialising in biologics, Wuxi Biologics offers a comprehensive range of services, from cell line development to commercial manufacturing. Their unique integrated platform streamlines the drug development process, enabling clients to bring innovative therapies to market more efficiently. With a strong commitment to quality and innovation, Wuxi Biologics has achieved significant milestones, including numerous partnerships with leading pharmaceutical companies, solidifying its position as a trusted partner in the global biopharmaceutical landscape.
DitchCarbon Score
How does Wuxi Biologics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Wuxi Biologics's score of 34 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Wuxi Biologics's reported carbon emissions
In 2023, Wuxi Biologics reported total carbon emissions of approximately 169,829,000 kg CO2e, comprising Scope 1 emissions of about 32,687,000 kg CO2e, Scope 2 emissions of approximately 149,229,000 kg CO2e, and Scope 3 emissions of around 21,012,30 kg CO2e from business travel, 19,654,270 kg CO2e from employee commuting, and additional emissions from waste and transportation activities. Wuxi Biologics has committed to achieving net-zero emissions across all scopes by 2050, with a commitment made in June 2023. This long-term target aligns with industry standards and reflects the company's dedication to sustainability within the pharmaceuticals and biotechnology sector. The company has also reported a total emission intensity of approximately 0.0000107 kg CO2e per unit of revenue for Scope 1 and Scope 2 combined, indicating a focus on reducing emissions relative to its financial growth. Overall, Wuxi Biologics is actively working towards significant climate commitments, aiming to reduce its carbon footprint while maintaining its position as a leader in the biotechnology industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 11,042,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 74,361,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Wuxi Biologics is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
